Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Myeloproliferative Disorders

Myeloproliferative Disorders

Myeloproliferative Disorders: A Comprehensive Guide

Myeloproliferative disorders are a group of blood cancers characterized by the overproduction of one or more types of blood cells.
These disorders can lead to a variety of symptoms and complications, including blood clots, bleeding, and an increased risk of progression to more serious forms of leukemia.
PubCompare.ai's AI-powered platform helps researchers explore this complex field, providing easy access to protocols from scholarly literature, preprints, and patents.
With insightful comparisons, you can identify the most effective and reproducibble approaches, optimizing your research for enhanced accuracy and reproducibility.
Discover the latest advancements in myeloproliferative disorder research and unlock new pathways for improved patient outcomes.
Explore PubCompare.ai today.

Most cited protocols related to «Myeloproliferative Disorders»

1
Thai Nationwide Atrial Fibrillation Registry
Cited 8 times
NVAF patients were consecutively enrolled from 24 hospitals located all across Thailand. Thirteen of those centers are university hospitals, and ten are regional or general hospitals. The protocol for this study was approved by the institutional review boards (IRBs) of the Thailand Ministry of Public Health and IRB of each participating hospital namely Buddhachinaraj Hospital, Central Chest Institute of Thailand, Charoen Krung Pracha Rak Hospital, Chiangrai Prachanukroh Hospital, Chonburi Hospital, Chiang Mai Hospital, King Chulalongkorn Memorial Hospital, Naresuan University Hospital, Songklanakarind Hospital, Ramathibodi Hospital, Siriraj Hospital, Thammasat Hospital, Golden Jubilee Medical Center, Srinakarind Hospital, Lampang Hospital, Maharat Nakorn Ratchasima Hospital, Nakornping Hospital, Phramongkutklao Hospital, Police General Hospital, Prapokklao Hospital (Chanthaburi), Ratchaburi Hospital, Surat Thani Hospital, Surin Hospital, and Udonthani Hospital. All patients provided written informed consent prior to participation in this study. Patients aged ≥18 years with atrial fibrillation diagnosed by standard ECG or ambulatory monitoring were eligible for inclusion. Patients having one or more of the following were excluded: 1) ischemic stroke within 3 months; 2) thrombocytopenia (< 100,000/mm3), myeloproliferative disorders, hyperviscosity syndrome, or antiphospholipid syndrome; 3) prosthetic valve or valve repair; 4) rheumatic valve disease or significant valve disease; 5) atrial fibrillation from transient reversible cause (e.g., during respiratory tract infection or bronchospasm); 6) ongoing participation in a clinical trial; 7) life expectancy less than 3 years; 8) pregnancy; 9) inability to attend scheduled follow-up appointments; 10) refusal to join the study; and/or, 11) current hospitalization or hospitalization within 1 month prior to inclusion in the study.
Baseline demographic and clinical data were collected and recorded. Patients were followed-up at 6, 12, 18, 24, 30, and 36 months. Data relating to cardiovascular events, blood pressure, heart rate, and medications were collected at each follow-up visit. Data from each patient was written on a case record form and keyed into a web-based data collection and management system. The following data were collected: 1) demographic information; 2) history of stroke and bleeding; 3) type and duration of atrial fibrillation; 4) component parameters of CHADS2 score, CHA2DS2VASc score for stroke risk, and HAS-BLED score for risk of bleeding; 5) history of medical and cardiovascular disease; 6) antithrombotic medication; 7) reason for not using warfarin in those not taking warfarin; 8) concomitant medications; 9) twelve-lead ECG; and, 10) current INR. Protocols were established and followed by the data management team and statisticians to ensure the integrity and quality of the data before final analysis. Random site monitoring was also regularly performed. Approximately 70% of sites were audited. Data were collected during the 2014 to 2017 study period.
Krittayaphong R., Winijkul A., Methavigul K., Wongtheptien W., Wongvipaporn C., Wisaratapong T., Kunjara-Na-Ayudhya R., Boonyaratvej S., Komoltri C., Kaewcomdee P., Yindeengam A, & Sritara P. (2018). Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovascular Disorders, 18, 174.
Full text: Click here
Publication 2018
Antiphospholipid Syndrome Atrial Fibrillation Blood Pressure Bronchospasm Cardiovascular Diseases Cardiovascular System Cerebrovascular Accident Chest Electrocardiography, 12-Lead Hospitalization Myeloproliferative Disorders Patients Pharmaceutical Preparations Pregnancy Rate, Heart Respiratory Tract Infections Rheumatism Stroke, Ischemic Syndrome Thrombocytopenia Transients Warfarin
2
Childhood Cancer Epidemiology: Pooled Analysis
Cited 7 times
Data were combined from five previous studies in which the incident cases of childhood cancer were identified from the population-based cancer registries of five states: California, Minnesota, New York (excluding New York City), Texas, and Washington. Cases were diagnosed between 1980 and 2004. The details of each state's selection and inclusion criteria have been previously reported 14 (link). Children up to age 14 years at diagnosis were included except in California where only cases less than 5 years of age were included (the CA study was originally designed to study early childhood cancers only). Cases were matched to birth certificates using probabilistic or sequential deterministic record linkage. Controls were randomly selected from each state's birth registry, in ratios to cases varying from 1:1 to 1:10 (differed by state). They were matched on date of birth in all states and also matched on sex in California and Texas. Any subject reported to have Down syndrome was excluded (n=100). Because subjects diagnosed before age 28 days were excluded in some of the states, this criterion was applied to all cases for consistency.
We classified the cancers according to the International Classification of Childhood Cancer (ICCC-3) and examined all groups with at least 200 cases 15 (link). We made one exception to this rule in order to examine the 109 cases of chronic myeloproliferative diseases (CMD) because of our interest in leukemia sub-types. Wilms tumors and retinoblastoma were further examined by unilateral and bilateral occurrence. Additionally we examined the CNS tumors by type to reflect clinically relevant biological differences using categories previously developed 16 . We classified pilocytic astrocytomas, astrocytomas not otherwise specified, and other grade I and II gliomas into the low grade glioma category. Malignant gliomas, anaplastic astrocytomas, and other grade III and IV gliomas were grouped into the high grade glioma category. Other separate categories included medulloblastomas, primitive neuroectodermal tumors (PNET), ependymomas, and intracranial/intraspinal germ cell tumors.
Odds ratios (OR) and 95% confidence intervals (CI) were calculated using unconditional logistic regression (SAS version 9.1). The individual matching of the California cases and controls was broken to allow the use of this procedure. The other states used frequency matching. We examined birth order in four categories: first, second, third, and fourth or more. In the multivariable analyses we adjusted for matching and pooling variables (state, sex, year of birth), maternal race, maternal age, singleton vs. multiple birth, gestational age, and birth weight (all categorized as shown in Table 2). We also stratified the analyses for the leukemia sub-types by age at diagnosis (0-4 years, 5-9 years, 10-14 years).
Von Behren J., Spector L.G., Mueller B.A., Carozza S.E., Chow E.J., Fox E.E., Horel S., Johnson K.J., McLaughlin C., Puumala S.E., Ross J.A, & Reynolds P. (2010). Birth order and Risk of Childhood Cancer: A Pooled Analysis from Five U.S. States. International journal of cancer. Journal international du cancer, 128(11), 2709-2716.
Publication 2010
Astrocytoma Astrocytoma, Anaplastic Biopharmaceuticals Birth Weight Central Nervous System Neoplasms Child Childbirth Diagnosis Down Syndrome Ependymoma Gestational Age Glioma Leukemia Malignant Glioma Malignant Neoplasms Medulloblastoma Mothers Multiple Birth Offspring Myeloproliferative Disorders Nephroblastoma Neuroectodermal Tumor, Primitive Pilocytic Astrocytoma Retinoblastoma Tumor, Germ Cell
3
Allogeneic HCT in AML Patients
Cited 6 times
AML patients ≥18 years of age were included in this retrospective study if they were in first morphologic CR or CR with incomplete peripheral blood count recovery (CRi) irrespective of the presence of MRD, underwent allogeneic HCT with NMA or MA conditioning, and received peripheral blood or bone marrow as stem cell source. We included all patients meeting these criteria if they underwent pre-HCT work up from late April 2006, when a refined MFC-based MRD detection method was introduced at our institution and utilized routinely in all patients, until April 2012. Results on the first 136 MA patients have been reported previously.8 (link), 9 (link) We used the 2008 WHO criteria to define AML12 (link) and the refined United Kingdom Medical Research Council (MRC) criteria to assign cytogenetic risk.13 (link) Secondary leukemia was defined as AML following a history of antecedent hematologic disorder (i.e. myelodysplastic syndrome or myeloproliferative neoplasm) or prior treatment with systemic chemotherapy and/or radiotherapy.
Pretransplantation comorbidities were assessed retrospectively using the HCT-specific comorbidity index (HCT-CI).14 (link), 15 (link) Treatment responses were categorized as proposed by the European LeukemiaNet.16 (link) Criteria for diagnosis and grading of acute and chronic GVHD have been reported previously.17 (link), 18 (link) Information on post-transplant outcomes was captured via the Long-Term Follow-Up Program through medical records from our outpatient clinic and local clinics that provided primary care for patients in addition to records obtained on patients on research studies. All patients were treated on Institutional Review Board-approved protocols or standard treatment protocols and gave consent in accordance with the Declaration of Helsinki. Follow-up was current as of October 1, 2013.
Walter R.B., Gyurkocza B., Storer B.E., Godwin C.D., Pagel J.M., Buckley S.A., Sorror M.L., Wood B.L., Storb R., Appelbaum F.R, & Sandmaier B.M. (2014). Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. Leukemia, 29(1), 137-144.
Publication 2014
BLOOD Blood Cell Count Bone Marrow Cells Diagnosis Ethics Committees, Research Europeans Grafts Hematological Disease Leukemia Myeloproliferative Disorders Patients Pharmacotherapy Radiotherapy Stem, Plant Syndrome, Myelodysplastic Treatment Protocols
4
Diagnostic Criteria and Outcomes in Polycythemia Vera
Cited 6 times
The International Working Group for Myeloproliferative Neoplasms (MPN) Research and
Treatment (IWG-MRT) meets annually to organize clinical research projects and develop
consensus criteria. The IWG-MRT recently published a series of papers that clarified the
natural history of WHO-defined essential thrombocythemia (ET) and its distinction from
prefibrotic myelofibrosis (MF).10 (link), 11 (link), 12 , 13 , 14 (link), 15 (link),
16 (link), 17 (link), 18 (link), 19 (link) During the 2010
IWG-MRT meeting in Florence, Italy, center and patient eligibility criteria for a large
international study in PV were discussed and followed up by a request for participation.
Study eligibility criteria included strict adherence to the 2008 WHO diagnostic
criteria,9 (link) availability of clinical and
laboratory information obtained within 1 year of diagnosis and before institution of
cytoreductive therapy, diagnosis date after 1970 and age ⩾18 years old.
After approval from their respective institutional review board, seven centers from
Italy, Austria and the United States collectively submitted diagnostic and follow-up
information on 1818 patients, locally diagnosed with ‘WHO-defined PV'. The two
principle investigators (AT and TB) reviewed all submitted cases and, based on diagnostic
accuracy9 (link) and the above stipulated
eligibility criteria, selected 1545 patients for further analysis (Supplementary Table 1). Conventional criteria were used for diagnosis of
post-PV acute myeloid leukemia (AML),9 (link) whereas
post-PV MF was annotated by the coinvestigators from each center with recommendations of
adherence to uniform criteria.20 (link) Conventional
laboratory methods were used by each institution for JAK2 mutation screening,
measurement of serum erythropoietin level and detection of endogenous erythroid
colonies.
All analyses were conducted using The Stat View (SAS Institute, Cary, NC, USA), JMP (SAS
Institute) or SAS version 9.2 (SAS Institute) statistical packages. Pre-receiver operating
characteristic (ROC) plots were used to determine cutoff levels for continuous variables
of interest.21 (link) Differences in the distribution
of continuous variables between categories were analyzed by Mann–Whitney or
Kruskal–Wallis test. Patient groups with nominal variables were compared by
χ2 test. Overall survival analysis was considered from the date
of diagnosis to date of death (uncensored) or last contact (censored). Observed survival
was compared with the expected survival of the age- and sex-matched US total population.
The rate of post-PV AML was calculated as the cumulative incidence of transformation,
accounting for the competing risk of death.22 (link)All survival curves were prepared by the Kaplan–Meier method and compared by the
log-rank test. Cox proportional hazard regression model was used for multivariable
analysis. P-values <0.05 were considered significant.
Tefferi A., Rumi E., Finazzi G., Gisslinger H., Vannucchi A.M., Rodeghiero F., Randi M.L., Vaidya R., Cazzola M., Rambaldi A., Gisslinger B., Pieri L., Ruggeri M., Bertozzi I., Sulai N.H., Casetti I., Carobbio A., Jeryczynski G., Larson D.R., Müllauer L., Pardanani A., Thiele J., Passamonti F, & Barbui T. (2013). Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 27(9), 1874-1881.
Publication 2013
Diagnosis Eligibility Determination Erythropoietin Ethics Committees, Research Janus Kinase 2 Leukemia, Myelocytic, Acute Mutation Myeloproliferative Disorders Patients Primary Myelofibrosis Serum Therapeutics Thrombocythemia, Essential
5
Febuxostat and Allopurinol in Gout Management
Cited 6 times
Subjects aged 18 to 85 years with a diagnosis of gout fulfilling American Rheumatology Association preliminary criteria [36 (link)] and sUA ≥ 8.0 mg/dL were eligible for enrollment. Subjects were enrolled at 324 sites in the United States. Institutional Review Board approval was obtained, and all subjects provided written informed consent and Health Insurance Portability and Accountability Act authorization prior to any study-related procedure. At least 35% of subjects enrolled were to have mild or moderate renal impairment, defined as baseline estimated creatinine clearance (eCLcr) of 60 to 89 ml/minutes or 30 to 59 ml/minutes, respectively, calculated by the Cockcroft-Gault formula corrected for ideal body weight [37 (link),38 (link)]. Subjects successfully completing either of two previously reported long-term, open-label febuxostat [13 (link)] or febuxostat/allopurinol [14 (link)] extension studies were also eligible for enrollment.
Exclusion criteria included: secondary hyperuricemia (for example, due to myeloproliferative disorder); xanthinuria; severe renal impairment (eCLcr <30 ml/minutes [37 (link),38 (link)]); alanine aminotransferase and aspartate aminotransferase values >1.5 times the upper limit of normal; consumption of more than 14 alcoholic drinks per week or a history of alcoholism or drug abuse within five years; or a medical condition that, in the investigator's opinion, would interfere with treatment, safety, or adherence to the protocol.
Subject screening evaluations included: physical examination and vital signs; medical history, a pre-specified CV history/risk form; laboratory tests (sUA, complete chemistry panel, hematology, urinalysis, and, for women, pregnancy test); echocardiogram; assessment for tophi and gout flare; and concomitant medication use. With the exception of tophus assessment, these elements, along with compliance, were repeated at bimonthly visits during the six-month treatment period. sUA was blinded after baseline determination at Day-4.
An Interactive Voice Response System was utilized by site personnel during screening visits to initiate double-blind randomization. Subjects were randomized 1:1:1 on Day 1 to receive daily febuxostat 40 mg, febuxostat 80 mg, or allopurinol (Apotex; Weston, FL, USA). Randomization was stratified by baseline renal function and prior completion of either of two open-label extension trials [13 (link),14 (link)]. Among subjects randomized to allopurinol, those with normal renal function or mild renal impairment received 300 mg daily, and those with moderate renal impairment received 200 mg.
During a 30-day washout period for subjects receiving prior ULT, and throughout the subsequent six-month treatment period for all subjects, prophylaxis for gout flares was given either as colchicine, 0.6 mg daily (West-Ward Pharmaceutical Corporation, Eatontown, NJ, USA) or naproxen, 250 mg twice daily (West-Ward Pharmaceutical Corporation). All subjects receiving naproxen prophylaxis also received lansoprazole 15 mg daily (Takeda Global Research & Development Center, Inc., Deerfield, IL, USA). Choice of prophylaxis regimen was made by the investigator and subject, taking into account prior drug tolerance and prophylaxis experience. In addition, subjects with eCLcr <50 ml/minute were not to receive naproxen. Gout flares were regarded as expected gout manifestations rather than as AEs.
Becker M.A., Schumacher H.R., Espinoza L.R., Wells A.F., MacDonald P., Lloyd E, & Lademacher C. (2010). The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research & Therapy, 12(2), R63.
Full text: Click here
Publication 2010
Alcoholic Beverages Alcoholic Intoxication, Chronic Allopurinol Aspartate Transaminase Colchicine Comprehensive Metabolic Panel Creatinine D-Alanine Transaminase Diagnosis Drug Abuse Echocardiography Ethics Committees, Research Febuxostat Gout Hyperuricemia Ideal Body Weight Kidney Lansoprazole Myeloproliferative Disorders Naproxen Pharmaceutical Preparations Physical Examination Pregnancy Tests Renal Insufficiency Safety Signs, Vital Treatment Protocols Urinalysis Woman

Most recents protocols related to «Myeloproliferative Disorders»

1
COVID-19 Severity Grading and Disease Status
Confirmed cases of COVID-19 were defined by a positive reverse transcription polymerase chain reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab.
The severity of COVID-19 at admission is graded according to the China Center for Disease Control and Prevention definitions (17 (link)).
Disease status at the time of SARS-CoV-2 detection was defined according to each specific disease’s revised criteria for leukemia, myeloproliferative neoplasm, multiple myeloma, and lymphoma. The ISI was calculated as previously described (4 (link)).
Busca A., Salmanton-García J., Marchesi F., Farina F., Seval G.C., Van Doesum J., De Jonge N., Bahr N.C., Maertens J., Meletiadis J., Fracchiolla N.S., Weinbergerová B., Verga L., Ráčil Z., Jiménez M., Glenthøj A., Blennow O., Tanase A.D., Schönlein M., Prezioso L., Khanna N., Duarte R.F., Žák P., Nucci M., Machado M., Kulasekararaj A., Espigado I., De Kort E., Ribera-Santa Susana J.M., Marchetti M., Magliano G., Falces-Romero I., Ilhan O., Ammatuna E., Zompi S., Tsirigotis P., Antoniadou A., Zambrotta G.P., Nordlander A., Karlsson L.K., Hanakova M., Dragonetti G., Cabirta A., Berg Venemyr C., Gräfe S., Van Praet J., Tragiannidis A., Petzer V., López-García A., Itri F., Groh A., Gavriilaki E., Dargenio M., Rahimli L., Cornely O.A, & Pagano L. (2023). Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Frontiers in Immunology, 14, 1125030.
Full text: Click here
Publication 2023
Biological Assay COVID 19 Leukemia Lymphoma Multiple Myeloma Myeloproliferative Disorders Nasopharynx Reverse Transcriptase Polymerase Chain Reaction
2
Evaluating Immune Checkpoint Inhibition in Leukemia
Bone marrow aspirates and peripheral blood samples were separated by Ficoll density gradient centrifugation. All experiments were performed using freshly isolated cells. Cells were labeled with CellTrace Violet (CTV, Thermo Fisher) and cultured in 96-well plates coated with 1 µg/mL anti-CD3 (BioLegend, Clone UCHT1) or control mIgG (BioLegend, Clone MOPC-21). Groups of wells were then treated with either 10 µg/mL control mIgG, 10 µg/mL anti-PD1 (EH12.2H7), 60 nM JQ1, or 60 nM JQ1 + 10 µg/mL anti-PD1. After 5 days, cells were stained for flow cytometry. Antibody clones and source are listed in Table 2. Viability was determined by Zombie Aqua staining and doublets were gated out of analysis by FSC-A vs. FSC-H. Flow cytometry data were acquired on a BD LSRFortessa or Cytek Aurora and analyzed using FlowJo v10 software. All human sample experiments are approved under IRB protocol #00004422, “Pathogenesis of Acute Leukemia, Lymphoproliferative Disorder and Myeloproliferative Disorders” (PI: Marc Loriaux, MD, PhD). Informed consent was obtained from all patients.

Antibodies used in this study for staining of patient samples.

MarkerCloneVendor
CD19HIB19BioLegend
CD45HI30BioLegend
CD8RPA-T8BioLegend
CTLA-4BNI3BioLegend
PDL129E.2A3BioLegend
CD33WM53BioLegend
CD4RPA-T4BioLegend
PDL224F.10C12BioLegend
CD56HCD56BioLegend
TIGITMBSA43Thermo Fisher
TIM37D3BD
PD1EH12.2H7BioLegend
CD3HIT3aBioLegend

List of specificity, clone and source of each antibody used in human flow cytometry experiments.

Romine K.A., MacPherson K., Cho H.J., Kosaka Y., Flynn P.A., Byrd K.H., Coy J.L., Newman M.T., Pandita R., Loo C.P., Scott J., Adey A.C, & Lind E.F. (2023). BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells. Leukemia, 37(3), 580-592.
Full text: Click here
Publication 2023
BLOOD Bone Marrow CCL7 protein, human Cells Centrifugation, Density Gradient Clone Cells CXCL9 protein, human Ficoll Flow Cytometry Homo sapiens Immunoglobulins Leukemia Lymphoproliferative Disorders Muromonab-CD3 Myeloproliferative Disorders pathogenesis Patients Viola
3
Hematopoietic Stem Cell Transplantation
Wherever appropriate, the absolute numbers of transplanted patients, number of transplants or transplant rates are shown for specific countries, indications, or transplant techniques. Myeloid malignancy include acute myeloid leukemia (AML), myelodysplastic or myelodysplastic/myeloproliferative neoplasia (MDS or MDS/MPN overlap), myeloproliferative neoplasm (MPN), and chronic myeloid leukemia (CML). Lymphoid malignancy include acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and plasma cell disorders (PCD) (including multiple myeloma (MM) and others). Non-malignant disorders include bone marrow failure (BMF: severe aplastic anemia (SAA) and other BMF), thalassemia and sickle cell disease (HG), primary immune deficiencies (PID), inherited diseases of metabolism (IDM), and autoimmune diseases (AID). Others include histiocytosis and other rare disorders.
Passweg J.R., Baldomero H., Ciceri F., Corbacioglu S., de la Cámara R., Dolstra H., Glass B., Greco R., McLornan D.P., Neven B., de Latour R.P., Perić Z., Ruggeri A., Snowden J.A, & Sureda A. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 58(6), 647-658.
Full text: Click here
Publication 2023
Anemia, Sickle Cell Aplastic Anemia Autoimmune Diseases Cell Dyscrasia, Plasma Chronic Lymphocytic Leukemia Grafts Histiocytosis Hodgkin Disease Leukemia, Myelocytic, Acute Leukemias, Chronic Granulocytic Lymph Lymphoma, Non-Hodgkin, Familial Malignant Neoplasms Metabolic Diseases Multiple Myeloma Myeloproliferative Disorders Pancytopenia Patients Precursor Cell Lymphoblastic Leukemia Lymphoma Primary Immune Deficiency Disorder Rare Diseases Thalassemia
4
Gene Expression Profiling of Myeloproliferative Neoplasms
Key word “myeloproliferative neoplasms” was used to search gene expression profiles of MPNs in the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) data portal. The following criteria were used to filter the obtained database: 1. The gene expression profiling must cover all types of chronic and progressed MPNs (PV, ET, PMF) and controls. 2. The cell used for sequencing should be CD34+ MNCs (mononuclear cell) from peripheral blood (PB) or bone marrow (BM). 3. The processed data or raw data from datasets must be provided thus could be available to reanalyze. 4. The GEO dataset numbered GSE136335, GSE145802 were selected. Further, anoikis-related genes (ARGs) were downloaded from the GeneCard database (https://www.genecards.org/).
Aini W., Xie L., Hu W., Tang Y., Peng H., Zhang G, & Deng T. (2023). Exploration and identification of anoikis-related genes in polycythemia vera. Frontiers in Genetics, 14, 1139351.
Full text: Click here
Publication 2023
Anoikis BLOOD Bone Marrow Cells Gene Expression Genes Myeloproliferative Disorders
5
Nationwide Multicenter Study of Non-valvular Atrial Fibrillation
The Cohort of Antithrombotic Use and Optimal INR Level in Patients with Non-valvular Atrial Fibrillation in Thailand (COOL-AF Thailand) registry was a prospective nationwide multicenter study of patients with non-valvular AF aged more than 18 years. The exclusion criteria were as follows: (i) rheumatic mitral valve disease; (ii) prosthetic mechanical valve; (iii) inability to have a follow-up visit; (iv) life expectancy less than 3 years; (v) AF from transient reversible cause; (vi) ischemic stroke of less than 3 months; (vii) hematologic disease that increased the risk of bleeding such as myeloproliferative disease; and (viii) refusal to participate.
The study was approved by the Central Research Ethics Committee (CREC) with the Certificate of Approval number COA-CREC 003/2014. Written informed consent was obtained prior to participation.
Krittayaphong R., Chichareon P., Komoltri C., Sairat P, & Lip G.Y. (2023). Predicting Heart Failure in Patients with Atrial Fibrillation: A Report from the Prospective COOL-AF Registry. Journal of Clinical Medicine, 12(4), 1265.
Full text: Click here
Publication 2023
Atrial Fibrillation Ethics Committees, Research Hematological Disease Mitral Valve Myeloproliferative Disorders Patients Rheumatism Stroke, Ischemic Transients

Top products related to «Myeloproliferative Disorders»

1
Poly 1 c by InvivoGen
Sourced in United States, France, Germany, Canada, China, Spain, Hong Kong, United Kingdom
Poly(I:C) is a synthetic double-stranded RNA (dsRNA) molecule that mimics the structure of viral RNA. It acts as an agonist of Toll-like receptor 3 (TLR3), triggering an innate immune response similar to that induced by viral infection.
2
Dna protein oligo conjugated antibodies by BioLegend
DNA+Protein oligo-conjugated antibodies are a type of lab equipment used for various biomedical research applications. These antibodies are conjugated with both DNA and protein oligonucleotides, allowing for multiplex detection and analysis. The core function of this product is to facilitate the simultaneous identification and quantification of multiple target molecules within a sample.
3
Cobas ampliprep cobas taqman hcv test by Roche
Sourced in United States, Germany, Japan
The COBAS AmpliPrep/COBAS TaqMan HCV Test is a diagnostic laboratory equipment product designed for the detection and quantification of Hepatitis C Virus (HCV) RNA in human serum or plasma samples. It utilizes real-time PCR technology to provide automated sample preparation and amplification, delivering reliable and accurate results.
4
Human trustain fcx by BioLegend
Sourced in United States, United Kingdom, China, Germany
Human TruStain FcX is a labeling reagent that blocks Fc receptors, reducing non-specific binding in flow cytometry experiments. It is designed to improve the specificity of antibody staining by minimizing background signal from Fc receptor interactions.
5
Trusight myeloid sequencing panel by Illumina
Sourced in United States
The TruSight Myeloid Sequencing Panel is a targeted next-generation sequencing assay designed to detect genetic variants associated with myeloid neoplasms. The panel covers over 50 key genes related to myeloid malignancies, enabling comprehensive genetic profiling of samples.
6
B6 cg mir146tm1.1bal j by Jackson ImmunoResearch
B6.Cg-Mir146tm1.1Bal/J is a laboratory mouse strain that carries a targeted mutation in the miR-146a gene. This strain is used in research to study the role of miR-146a in various biological processes.
7
Cd34 microbead kit ultrapure by Miltenyi Biotec
Sourced in Germany, United States, France
The CD34 MicroBead Kit UltraPure is a laboratory equipment product designed for the isolation and enrichment of CD34+ cells from various sample types. It utilizes magnetic beads coated with anti-CD34 antibodies to selectively bind and separate the target cells.
8
Infinium humanmethylation450k beadchip by Illumina
Sourced in United States
The Infinium HumanMethylation450K BeadChip is a lab equipment product designed for genome-wide DNA methylation analysis. It targets over 485,000 methylation sites across the human genome, providing a comprehensive view of the methylome. The BeadChip is intended for use in epigenetic research applications.
9
α mem by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, Japan, Australia, France, Italy, Canada, Switzerland, New Zealand, Netherlands, Denmark, Israel, Thailand, Holy See (Vatican City State), Argentina, Ireland
α-MEM is a cell culture medium formulated for the growth and maintenance of mammalian cells. It provides a balanced salt solution, amino acids, vitamins, and other nutrients required for cell proliferation.

More about "Myeloproliferative Disorders"

Myeloproliferative Disorders: Exploring the Complex Landscape of Blood Cancers Myeloproliferative disorders (MPDs) are a group of rare and diverse blood cancers characterized by the overproduction of one or more types of blood cells, including red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes).
These disorders can lead to a variety of symptoms and complications, such as blood clots, bleeding, and an increased risk of progression to more aggressive forms of leukemia.
The field of MPD research is rapidly evolving, with a wealth of scholarly literature, preprints, and patents exploring new frontiers in diagnosis, treatment, and management.
Synonyms for MPDs include myeloproliferative neoplasms (MPN) and chronic myeloproliferative disorders (CMPD), which are often used interchangeably.
Key subtopics in MPD research include the role of genetic mutations, such as those in the JAK2, CALR, and MPL genes, in driving disease pathogenesis.
Cutting-edge techniques like Poly(I:C) stimulation, DNA+Protein oligo-conjugated antibodies, and the COBAS AmpliPrep/COBAS TaqMan HCV Test are used to study disease mechanisms and develop novel therapeutic approaches.
The utilization of flow cytometry with the Human TruStain FcX, TruSight Myeloid Sequencing Panel, and CD34 MicroBead Kit UltraPure are crucial for accurate diagnosis and disease monitoring.
Additionally, epigenetic profiling using the Infinium HumanMethylation450K BeadChip can provide valuable insights into disease heterogeneity and progression.
Researchers can leverage PubCompare.ai's AI-powered platform to explore the latest advancements in MPD research, accessing protocols from a diverse range of scholarly sources and identifying the most effective and reproducible approaches.
By optimizing their research with PubCompare.ai's tools, scientists can enhance the accuracy and reproducibility of their studies, ultimately leading to improved patient outcomes.
Whether you're studying the underlying biology of MPDs, developing novel diagnostic methods, or exploring innovative therapeutic strategies, PubCompare.ai is your gateway to the cutting edge of this complex and rapidly evolving field.